CRANFORD, N.J., March 26, 2020 /PRNewswire/ -- Citius
Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a
specialty pharmaceutical company focused on adjunctive cancer care
and critical care drug products, announced today the publication of
an in vitro study for Mino-Lok®, the Company's antibiotic lock
solution used to treat patients with central line associated blood
stream infections (CLABSIs) and catheter-related bloodstream
infections (CRBSIs), in the March
2020 issue of Antimicrobial Agents and
Chemotherapy. The article, titled
"Minocycline-EDTA-Ethanol Antimicrobial Catheter Lock Solution Is
Highly Effective In Vitro for Eradication of Candida
auris Biofilms," highlights the in vitro efficacy of
Mino-Lok against various strains of Candida auris ("C.
auris") from studies conducted at MD Anderson Cancer Center
Labs.
Mr. Myron Holubiak, Chief
Executive Officer of Citius, said, "We're happy to have the
positive preclinical results of Mino-Lok published in the
AAC Journal. Candida auris is a very problematic type
of fungus, but the results from these in vitro
studies showed that complete eradication of all strains of C.
auris occurred within an hour of exposure to Mino-Lok. We
anticipate completing our Phase 3 trial with Mino-Lok by the end of
2020, which will bring us one step closer to treating patients with
infected catheters from any number of fungi or
bacteria."
C. auris is a fungus that can cause serious
bloodstream infections or death, particularly in hospital and
nursing home patients with serious medical problems. More than one
in three patients with invasive C. auris infection die. The
fungus is often resistant to most antifungal agents commonly used
to treat Candida infections. Although C. auris was just
recently discovered in 2009, it has spread quickly and caused
infections in more than a dozen countries. Patients who have been
hospitalized in a healthcare facility a long time, have a central
venous catheter or other lines or tubes entering their body, or
have previously received antibiotics or antifungal medications,
appear to be at highest risk of infection with this yeast.
About Mino-Lok®
Each year, more than 330,000 central venous catheters out of the
7 million used in the U.S. become infected and lead to CRBSIs,
increasing both patient morbidity risk and costs to the medical
system. It has been shown that antibiotics alone are unable to
penetrate the biofilm caused by bacteria, and there are currently
no approved therapies for salvaging infected central venous
catheters. Mino-Lok is an antibiotic lock solution that is being
developed to treat patients with CRBSIs in combination with an
appropriate systemic antibiotic(s) to preserve central venous
access and to avoid the complications and morbidities associated
with catheter removal and reinsertion. Mino-Lok penetrates biofilm,
eradicates bacteria and salvages infected, indwelling vascular
catheters while providing anticlotting properties. Mino-Lok has the
potential to change the standard of care for the management of
these serious infections.
About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the
development and commercialization of critical care products, with a
focus on anti-infectives, cancer care, and unique prescription
products that use innovative, patented, or proprietary formulations
of previously-approved active pharmaceutical ingredients. We seek
to achieve leading market positions by providing therapeutic
products that address unmet medical needs. By using
previously approved drugs with substantial safety and efficacy
data, we seek to reduce the risks associated with pharmaceutical
product development and regulatory requirements. Citius develops
products that have intellectual property protection and competitive
advantages to existing therapeutic approaches. For more
information, please visit www.citiuspharma.com.
Safe Harbor
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
are made based on our expectations and beliefs concerning future
events impacting Citius. You can identify these statements by the
fact that they use words such as "will," "anticipate," "estimate,"
"expect," "should," and "may" and other words and terms of similar
meaning or use of future dates. Forward-looking statements are
based on management's current expectations and are subject to risks
and uncertainties that could negatively affect our business,
operating results, financial condition and stock price.
Factors that could cause actual results to differ materially from
those currently anticipated are: risks associated with conducting
our Phase 3 trial for Mino-Lok, including completing patient
enrollment and achieving the required number of catheter failure
events; the estimated markets for our product candidates and the
acceptance thereof by any market; our need for substantial
additional funds; risks associated with developing Mino-Wrap,
including that preclinical results may not be predictive of
clinical results and our ability to file an IND; risks related to
our growth strategy; our ability to identify, acquire, close and
integrate product candidates and companies successfully and on a
timely basis; risks relating to the results of research and
development activities; uncertainties relating to preclinical and
clinical testing; the early stage of products under development;
our ability to obtain, perform under and maintain financing and
strategic agreements and relationships; our ability to attract,
integrate, and retain key personnel; government regulation; patent
and intellectual property matters; competition; as well as other
risks described in our SEC filings. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based,
except as required by law.
Contact:
Andrew
Scott
Vice President, Corporate
Development
(O) 908-967-6677 x105
ascott@citiuspharma.com
View original
content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-publication-in-antimicrobial-agents-and-chemotherapy-journal-of-positive-preclinical-results-for-mino-lok-in-rapidly-eradicating-candida-auris-301030124.html
SOURCE Citius Pharmaceuticals, Inc.